188 related articles for article (PubMed ID: 28070882)
1. Effect of a 180 mg ticagrelor loading dose on myocardial necrosis in patients undergoing elective percutaneous coronary intervention: A preliminary study.
Xu Q; Sun Y; Zhang Y; Liu B; Fang L; Shen C; Li Y; Meng S
Cardiol J; 2017; 24(1):15-24. PubMed ID: 28070882
[TBL] [Abstract][Full Text] [Related]
2. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
3. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
[TBL] [Abstract][Full Text] [Related]
4. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
Silvain J; Lattuca B; Beygui F; Rangé G; Motovska Z; Dillinger JG; Boueri Z; Brunel P; Lhermusier T; Pouillot C; Larrieu-Ardilouze E; Boccara F; Labeque JN; Guedeney P; El Kasty M; Laredo M; Dumaine R; Ducrocq G; Collet JP; Cayla G; Blanchart K; Kala P; Vicaut E; Montalescot G;
Lancet; 2020 Nov; 396(10264):1737-1744. PubMed ID: 33202219
[TBL] [Abstract][Full Text] [Related]
6. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
[TBL] [Abstract][Full Text] [Related]
7. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
Dehghani P; Lavoie A; Lavi S; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN
Am Heart J; 2017 Oct; 192():105-112. PubMed ID: 28938956
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes.
Bonello L; Laine M; Cluzel M; Frere C; Mancini J; Hasan A; Thuny F; Gaubert M; Guieu R; Dignat-George F; Michelet P; Paganelli F; Kerbaul F
Am J Cardiol; 2015 Aug; 116(3):339-43. PubMed ID: 26037292
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
[TBL] [Abstract][Full Text] [Related]
11. Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
Wu X; Liu G; Lu J; Zheng XX; Cui JG; Zhao XY; Huang XH
Int Heart J; 2017 Apr; 58(2):167-173. PubMed ID: 28321022
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
[TBL] [Abstract][Full Text] [Related]
13. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
[TBL] [Abstract][Full Text] [Related]
15. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
16. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
De Backer O; Ratcovich H; Biasco L; Pedersen F; Helqvist S; Saunamäki K; Tilsted HH; Clemmensen P; Olivecrona G; Kelbaek H; Jørgensen E; Engstrøm T; Holmvang L
Thromb Haemost; 2015 Aug; 114(3):623-31. PubMed ID: 25994355
[TBL] [Abstract][Full Text] [Related]
17. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
18. Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Clavijo LC; Maya J; Carlson G; Angiolillo DJ; Teng R; Caplan R; Price MJ
Cardiovasc Revasc Med; 2015 Dec; 16(8):450-4. PubMed ID: 26440227
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
Singh S; Singh M; Grewal N; Khosla S
Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
